Drug Delivery Business

Dexcom

Dexcom wins FDA nod for 15-day CGM

By

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system. The clearance covers people over the age of 18 years old in the U.S. It makes the G7, Dexcom’s latest-generation CGM, the longest-lasting wearable CGM, according to the company. San Diego–based Dexcom submitted its 15-day G7 CGM to the […]

Dexcom picks longtime Masimo exec as next CCO

By

Dexcom (Nasdaq:DXCM) announced today that it appointed Jon Coleman as its new chief commercial officer (CCO). Coleman assumes responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience. He takes over for Teri Lawver, who in October announced her plans to retire as CCO of the continuous glucose monitor (CGM) maker. At […]

Nanowear enters CGM licensing, data partnership with Dexcom

By

Nanowear announced today that it entered into a partnership with Dexcom to ingest glucose data from its latest continuous glucose monitors (CGMs). The partnership will see Nanowear’s SimpleSense nanotechnology-enabled wearable, mobile and software diagnostics platform take data from the Dexcom G7 CGM, combining continuous glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics. This […]

The biggest diabetes tech news out of ATTD 2025

By

Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]

Why Dexcom is making a push to bring CGM to more people with type 2 diabetes

By

Of the hundreds of millions of people living with diabetes, the vast majority live with type 2. Dexcom (Nasdaq:DXCM) wants to make sure they have the tools to manage that. The International Diabetes Federation says that more than 90% of people with diabetes have type 2 diabetes. Yet, that population remains significantly under-penetrated by the […]

Dexcom CGM now connects with Novo Nordisk smart insulin pens, 15-day CGM shows promise

By

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors (CGMs). The company shared its updates at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Amsterdam. It also revealed new findings about attitudes toward the use of technology in the type 2 diabetes population. Today, […]

Dexcom study finds that providers prefer tech over medication for type 2 diabetes

By

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments. The “Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East” surveyed 2,500 people. It featured individuals with type 2 diabetes and healthcare professionals across Germany, Italy, the Netherlands, Saudi Arabia, Spain and the […]

Dexcom receives FDA warning letter

By

Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company facilities. The letter followed inspections of the company’s plants in San Diego and Mesa, Arizona. San Diego is where Dexcom’s headquarters is located, while the company last year decided to move manufacturing out of San Diego to […]

Data outlines need for CGM study design guidelines

By

A study looking at three leading continuous glucose monitors (CGMs), including systems from Abbott and Dexcom, signaled the need for new guidelines, investigators say. Published in the Journal of Diabetes Science and Technology, the study evaluated the latest-generation Abbott FreeStyle Libre 3, Dexcom G7 and Medtronic Simplera CGMs against different comparator methods and during clinically […]

Dexcom posts Q4 EPS miss, analysts remain high on coming catalysts

By

Dexcom (Nadsaq:DXCM) announced fourth-quarter results that came in mixed compared to the consensus forecast — but analysts are optimistic about 2025. Shares of DXCM initially fell after-hours yesterday on the after-market-close report — but by midday today, they were up more than 5% to $89.03 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported […]